Comparative Real‐World Effectiveness of Anti‐TNF, Ustekinumab and Vedolizumab in Crohn's Disease Over 24 Months: A Pooled Analysis From the Prospective UMBRELLA‐IBD Registry in Germany

Arne Bokemeyer, Florian Tran, Sandra Plachta‐Danielzik, Elena Gilman, Thomas Wenske, Matthew Gaskins, Stefan Schreiber, Bernd Bokemeyer · 2026

Read Comparative Real‐World Effectiveness of Anti‐TNF, Ustekinumab and Vedolizumab in Crohn's Disease Over 24 Months: A Pooled Analysis From the Prospective UMBRELLA‐IBD Registry in Germany by Arne Bokemeyer, Florian Tran, Sandra Plachta‐Danielzik, Elena Gilman, Thomas Wenske, Matthew Gaskins, Stefan Schreiber, Bernd Bokemeyer (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13511377.txt.

Description

Arne Bokemeyer and seven co-authors pool German registry data to compare three biologic drug families for Crohn disease under routine care, in 2026 work. The analysis covered 1567 adults who started an anti-TNF drug, ustekinumab, or vedolizumab, drawn from three prospective registries joined in one data warehouse. Outcomes ran over 24 months and included remission on a standard bowel activity score, quality of life, and how long patients stayed on their drug.

After early treatment, remission was slightly more common with anti-TNF drugs than with the other two. By 24 months the picture flipped, with ustekinumab ahead of anti-TNF on remission while vedolizumab sat between. Staying on therapy differed too, highest for one anti-TNF drug and lowest for the other. Symptom scores fell and stayed low in all groups. The authors say overall performance was strong, with gaps that were real yet modest.

Catalog record

CREATORArne Bokemeyer, Florian Tran, Sandra Plachta‐Danielzik, Elena Gilman, Thomas Wenske, Matthew Gaskins, Stefan Schreiber, Bernd Bokemeyer
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE48654
LICENSEhttps://creativecommons.org/licenses/by/4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/article/MED/PMC13511377

Browse the full library · About the Tower of Babel